Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Lancet Reg Health Am ; 21: 100484, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37096191

RESUMEN

Background: Antimicrobial resistance (AMR) is among the most critical global health threats of the 21st century. AMR is primarily driven by the use and misuse of antibiotics but can be affected by socioeconomic and environmental factors. Reliable and comparable estimates of AMR over time are essential to making public health decisions, defining research priorities, and evaluating interventions. However, estimates for developing regions are scant. We describe the evolution of AMR for critical priority antibiotic-bacterium pairs in Chile and examine their association with hospital and community-level characteristics using multivariate rate-adjusted regressions. Methods: Drawing on multiple data sources, we assembled a longitudinal national dataset to analyse AMR levels for critical priority antibiotic-bacterium combinations in 39 private and public hospitals (2008-2017) throughout the country and characterize the population at the municipality level. We first described trends of AMR in Chile. Second, we used multivariate regressions to examine the association of AMR with hospital characteristics and community-level socioeconomic, demographic, and environmental factors. Last, we estimated the expected distribution of AMR by region in Chile. Findings: Our results show that AMR for priority antibiotic-bacterium pairs steadily increased between 2008 and 2017 in Chile, driven primarily by Klebsiella pneumoniae resistant to third-generation cephalosporins and carbapenems, and vancomycin-resistant Enterococcus faecium. Higher hospital complexity, a proxy for antibiotic use, and poorer local community infrastructure were significantly associated with greater AMR. Interpretation: Consistent with research in other countries in the region, our results show a worrisome increase in clinically relevant AMR in Chile and suggest that hospital complexity and living conditions in the community may affect the emergence and spread of AMR. Our results highlight the importance of understanding AMR in hospitals and their interaction with the community and the environment to curtail this ongoing public health crisis. Funding: This research was supported by the Agencia Nacional de Investigación y Desarrollo (ANID), Fondo Nacional de Desarrollo Científico y Tecnológico FONDECYT, The Canadian Institute for Advanced Research (CIFAR), and Centro UC de Políticas Públicas, Pontificia Universidad Católica de Chile.

2.
Antibiotics (Basel) ; 11(9)2022 Sep 07.
Artículo en Inglés | MEDLINE | ID: mdl-36139987

RESUMEN

Carbapenem-resistant Enterobacterales (CRE) is a critical public health problem in South America, where the prevalence of NDM metallo-betalactamases has increased substantially in recent years. In this study, we used whole genome sequencing to characterize a multidrug-resistant (MDR) Klebsiella pneumoniae (UCO-361 strain) clinical isolate from a teaching hospital in Chile. Using long-read (Nanopore) and short-read (Illumina) sequence data, we identified a novel un-typeable megaplasmid (314,976 kb, pNDM-1_UCO-361) carrying the blaNDM-1 carbapenem resistance gene within a Tn3000 transposon. Strikingly, conjugal transfer of pNDM-1_UCO-361 plasmid only occurs at low temperatures with a high frequency of 4.3 × 10-6 transconjugants/receptors at 27 °C. UCO-361 belonged to the ST1588 clone, previously identified in Latin America, and harbored aminoglycoside, extended-spectrum ß-lactamases (ESBLs), carbapenem, and quinolone-resistance determinants. These findings suggest that blaNDM-1-bearing megaplasmids can be adapted to carriage by some K. pneumoniae lineages, whereas its conjugation at low temperatures could contribute to rapid dissemination at the human-environmental interface.

3.
J Wound Care ; 31(Sup3): S51-S52, 2022 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-35348356

RESUMEN

This case study describes the combined use of a wound contact layer dressing containing collagen with negative pressure wound therapy (NPWT) on a diabetic foot ulcer (DFU). The patient was treated at a university hospital in Santiago, Chile. A wound size reduction of 58% was observed within the first 10 weeks of treatment, and the wound went on to heal fully over the next 14 weeks. The combined use of collagen and NPWT helped to initiate healing and prevent amputation of the foot. At 64, the patient was able to maintain his independence and quality of life.


Asunto(s)
Diabetes Mellitus , Pie Diabético , Terapia de Presión Negativa para Heridas , Colágeno/uso terapéutico , Pie Diabético/terapia , Humanos , Calidad de Vida , Cicatrización de Heridas
4.
J Wound Care ; 30(LatAm sup 1): 19-20, 2021 Aug 01.
Artículo en Español | MEDLINE | ID: mdl-34558975

RESUMEN

Use of collagen and negative pressure wound therapy in a diabetic foot ulcer: a case study SINOPSIS: The following case study describes the use of a collagen layer in combination with negative pressure wound therapy in a diabetic foot ulcer, treated in a hospital in Chile. The wound reduced 58% in size in the first 10 weeks of treatment, reaching complete healing in the following 14 weeks. The treatment carried out avoided amputation of the foot of the patient who, at 64 years of age, maintained his independence and quality of life.


Resumen: El siguiente caso de estudio describe el uso de una capa de colágeno en combinación con terapia de presión negativa en una úlcera de pie diabético, tratada en un hospital de Chile. La herida redujo su tamaño 58% en las primeras 10 semanas, y alcanzó la cicatrización completa en las siguientes 14 semanas. El tratamiento realizado evitó la amputación del pie del paciente que, a sus 64 años, mantuvo su independencia y calidad de vida.


Asunto(s)
Diabetes Mellitus , Pie Diabético , Terapia de Presión Negativa para Heridas , Amputación Quirúrgica , Colágeno , Pie Diabético/terapia , Humanos , Calidad de Vida
5.
Rev. chil. anest ; 50(5): 671-678, 2021. ilus, tab
Artículo en Español | LILACS | ID: biblio-1532553

RESUMEN

INTRODUCTION: The experience of restructuring a clinical surgical-anesthetic unit into a critical patient unit in charge of surgical- anesthetic personnel is presented during the period from May to July 2020 in the context of a SARS-CoV-2 pandemic. OBJECTIVES: Describe the unit's restructuring process, considering technical aspects, changes in staff functions, clinical outcomes of the patients, quality indicators obtained and the psychological impact on the healthcare team. MATHERIAL AND METHODS: The strategies implemented by the responsible experts were described (ie: engineering). Clinical data were obtained from an insti- tutional database and electronical medical records. The management of human resources was described using administrative records of the services of anesthesiology, OR and critical patient unit. The psychological impact on the unit staff was evaluated by applying the Maslach questionnaire. The quality of the clinical management of the unit was obtained from the compilation of standardized quality indicators for the critical patient units of the institution. RESULTS: 25 patients were admitted in the unit. The mean age was 62 ± 12 years. About the complications, 52% had pulmonary embolism, 36% had acute kidney injury, and 1 patient died. The prevalence of Burnout Syndrome was 73.6%. The occurrence of adverse events was minimal. DISCUSSION: The transformation of an anesthetic-surgical unit into a COVID critical patient one, demands a complex net of coordinated strategies to allow facing the attention demand with positive clinical results, at the expense of the health care team mental health.


INTRODUCCIÓN: Se presenta la experiencia de reconversión de una unidad de cuidados posanestésicos a una unidad de cuidados intensivos a cargo de personal anestésico-quirúrgico entre mayo y julio de 2020, en contexto de pandemia por SARS-CoV-2. OBJETIVOS: Describir el proceso de reconversión considerando aspectos técnicos, pertinentes al recurso humano, resultados clínicos, indicadores de calidad e impacto psicológico en el equipo de salud. MATERIALES Y MÉTODOS: Se describen las estrategias implementadas por los expertos responsables. Se obtienen datos clínicos desde base de datos institucional y ficha clínica electrónica. Se describe la gestión del recurso humano utilizando registros administrativos de los servicios involucrados. El impacto psicológico en el personal fue evaluado aplicando el cuestionario de Maslach. La calidad de la gestión clínica se obtiene a partir de indicadores de calidad estandarizados para las unidades de pacientes críticos de nuestro establecimiento. RESULTADOS: Se atendieron 25 pacientes en la unidad. La edad promedio fue 62 ± 12 años. El 52% presentó tromboembolismo pulmonar, 36% injuria renal aguda como complicación. Un paciente falleció. La prevalencia de síndrome de Burnout fue de 73,6%. La ocurrencia de eventos adversos fue baja. CONCLUSIONESConclusiones: La reconversión de una unidad anestésico-quirúrgica a una unidad crítica COVID-19, demanda un complejo entramado de estrategias coordinadas que permiten responder a la demanda de atención con resultados clínicos positivos, a expensas del costo de la salud mental del equipo de salud involucrado.


Asunto(s)
Humanos , Quirófanos/organización & administración , COVID-19/terapia , Unidades de Cuidados Intensivos/organización & administración , Reconversión de Camas , Agotamiento Profesional/epidemiología , Encuestas y Cuestionarios , Personal de Salud/psicología , Cuidados Críticos/organización & administración , Pandemias , Equipo de Protección Personal , SARS-CoV-2 , COVID-19/prevención & control , Hospitales Universitarios/organización & administración
7.
J Glob Antimicrob Resist ; 21: 1-2, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32061814

RESUMEN

OBJECTIVES: Serratia marcescens is a neglected opportunistic pathogen of public-health concern, especially due to its antimicrobial resistance features. Here we report the draft genome sequence of the first KPC-2 and SRT-2 co-producing S. marcescens strain (UCO-366) recovered from a catheter tip culture of a hospitalised patient in Santiago, Chile, in 2014. METHODS: Whole genomic DNA of strain UCO-366 was extracted and was sequenced using an Illumina NextSeq platform. De novo genome assembly was performed using Unicycler v.0.4.0 and the genome was annotated by the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) v.4.8. Genomic features were analysed using bioinformatic tools available at the Center for Genomic Epidemiology, the Comprehensive Antibiotic Resistance Database (CARD) and Pathosystems Resource Integration Center (PATRIC). RESULTS: The genome size of strain UCO-366 was 5 267 357bp, with a G+C content of 59.7% and comprising 5299 coding sequences (CDS), 42 tRNAs and 115 pseudogenes. The genome of UCO-366 also included an IncL/M plasmid. The resistome comprised various antimicrobial resistance genes (ARGs) conferring resistance to carbapenems, cephalosporins, aminoglycosides, sulfonamides, chloramphenicol, rifampicin and fluoroquinolones. Importantly, S. marcescens UCO-366 harboured blaKPC-2 and blaSRT-2, representing the first description of these ß-lactamase genes in this species in Chile. CONCLUSION: Here we report the genome of the first KPC-positive multidrug-resistant S. marcescens strain identified in Chile, which co-harboured several ARGs. The genome sequence of S. marcescens UCO-366 provides an insight into the antimicrobial resistance characteristics of this species in this country and offers important data for further genomic studies on this critical priority pathogen.


Asunto(s)
Farmacorresistencia Bacteriana Múltiple , Serratia marcescens , Chile , Farmacorresistencia Bacteriana Múltiple/genética , Genoma Bacteriano , Humanos , Serratia marcescens/genética , beta-Lactamasas/genética
8.
Rev. chil. infectol ; 36(6): 687-697, dic. 2019. tab
Artículo en Español | LILACS | ID: biblio-1058100

RESUMEN

Resumen Introducción: Vancomicina, terapia estándar para enterococos y estafilococos resistentes a β-lactámicos tradicionales (Staphylococcus aureus [SARM] y Staphylococcus coagulasa negativa), tiene extenso uso empírico en infecciones nosocomiales. Farmacológicamente débil, de estrecho margen terapéutico y farmacocinética poco predecible, es un fármaco sub-estándar según criterios contemporáneos. Tiene excesivo uso, por sobrediagnóstico de infecciones bacterianas y, en infecciones genuinas, por sobre-estimación etiológica de patógenos β-lactámico-resistentes. Últimamente han surgido nuevas amenazas a su efectividad: peores desenlaces en infecciones por SARM con CIM en rango alto de sensibilidad y resistencia de enterococos. Hay frecuente administración inadecuada en: dosis e intervalos, ausencia de dosis de carga inicial, falta de monitoreo con concentraciones plasmáticas, inadecuada dosificación en presencia de insuficiencia renal o diálisis e, importantemente, mantención de uso en ausencia de clara documentación de su necesidad. Nuevos fármacos anti-estafilocócicos no han permitido un reemplazo generalizado de vancomicina por lo que ésta mantiene un importante rol en la medicina contemporánea. Conclusiones: Una comprensión de las fortalezas y debilidades del fármaco, así como de la cambiante epidemiología y propiedades microbiológicas de los patógenos relevantes, al igual que un uso prudente y selectivo, permitirán optimizar su uso y mantener su rol terapéutico en la medicina actual y futura.


Background: Vancomycin, standard parenteral therapy for Gram positive cocci resistant to traditional beta-lactam antibiotics (Staphylococcus aureus and coagulase negative staphylococci [CNS]) and Enterococcus spp, frequent agents of nosocomial infections, is extensively used empirically in that setting. However, its pharmacological weakness, narrow therapeutic margin and poorly predictable pharmacokinetics, make it a suboptimal drug according to contemporary criteria. Vancomycin is over utilized due to both, overestimation of bacterial infections and, in genuine cases, overestimation of the etiological role of these resistant cocci, either nosocomially or community acquired. New threats narrow further its therapeutic role: poorer outcomes in infections with higher vancomycin MIC and resistance by enterococci. It is frequently given at inappropriate dosage and intervals, failing to: give loading dose when recommended, measure blood levels, adjust dosing to changing renal function and continued use when not necessary. Newer anti staphylococcal drugs haven't replaced completely the role of vancomycin, which maintains its usefulness in contemporary medicine. Conclusion: Understanding the strengths and weaknesses of vancomycin, current epidemiology and microbiology of infections for which it may be indicated, as well as the proper administration and monitoring, together with a prudent and selective indication will allow to preserve its present and future utility in the changing medical scenario.


Asunto(s)
Humanos , Infecciones Estafilocócicas/tratamiento farmacológico , Vancomicina , Staphylococcus , Pruebas de Sensibilidad Microbiana , Enterococcus , Antibacterianos/uso terapéutico
9.
Int J Infect Dis ; 81: 28-30, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30738908

RESUMEN

Carbapenemase-producing Enterobacteriaceae have rapidly disseminated worldwide and can colonize patients in healthcare centers. As in Chile the first isolations of NDM-1 and OXA-370 carbapenemases were related with a patient arriving from Brazil, the genetic relatedness of Klebsiella pneumoniae strains producers of these enzymes and isolated in both countries was assessed. PFGE analyses revealed that the isolates were clonally related, illustrating how travel contributes to the spread of multidrug-resistant microorganisms. In addition, the occurrence of three different carbapenemases in three different K. pneumoniae strains isolated from a single patient is described.


Asunto(s)
Proteínas Bacterianas/genética , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/genética , beta-Lactamasas/genética , Antibacterianos , Brasil/epidemiología , Chile/epidemiología , Farmacorresistencia Bacteriana Múltiple/genética , Humanos , Infecciones por Klebsiella/epidemiología , Klebsiella pneumoniae/enzimología , Pruebas de Sensibilidad Microbiana
10.
Artículo en Inglés | MEDLINE | ID: mdl-30627427

RESUMEN

Background: Healthcare-associated infections (HAIs) have a major impact on public health worldwide. Particularly, hospital surfaces contaminated with bacterial pathogens are often the origin of both sporadic cases and outbreaks of HAIs. It has been demonstrated that copper surfaces reduce the microbial burden of high touch surfaces in the hospital environment. Here we report the antimicrobial characterization of a novel composite coating with embedded copper particles, named Copper Armour™. Methods: The Copper Armour™ bactericidal activity was evaluated in in vitro assays against several bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli O157:H7 and Listeria monocytogenes. Additionally, its antimicrobial properties were also evaluated in a pilot study over a nine-week period at an adult intensive care unit. For this, four high touch surfaces, including bed rails, overbed table, bedside table and IV Pole, were coated with Cooper Armour™, and its microbial burden was determined over a nine-week period. Results: Copper Armour™ coated samples showed an in vitro reduction in bacterial burden of > 99.9% compared to control samples. Moreover, pilot study results indicate that Copper Armour™ significantly reduces the level of microbial contamination on high-touch surfaces in the hospital environment, as compared with standard surfaces. Conclusions: Based on its antimicrobial properties, Copper Armour™ is a novel self-sanitizing coating that exhibits bactericidal activity against important human pathogens and significantly reduces the microbial burden of hospital surfaces. This composite could be used as a self-sanitizing coating to complement infection control strategies in healthcare facilities.


Asunto(s)
Cobre/farmacología , Infección Hospitalaria/prevención & control , Desinfectantes/farmacología , Bacterias/efectos de los fármacos , Bacterias/crecimiento & desarrollo , Cobre/química , Infección Hospitalaria/microbiología , Desinfectantes/química , Contaminación de Equipos/prevención & control , Equipos y Suministros de Hospitales/microbiología , Humanos , Control de Infecciones , Proyectos Piloto
11.
Rev Chilena Infectol ; 36(6): 687-697, 2019 Dec.
Artículo en Español | MEDLINE | ID: mdl-33660747

RESUMEN

BACKGROUND: Vancomycin, standard parenteral therapy for Gram positive cocci resistant to traditional beta-lactam antibiotics (Staphylococcus aureus and coagulase negative staphylococci [CNS]) and Enterococcus spp, frequent agents of nosocomial infections, is extensively used empirically in that setting. However, its pharmacological weakness, narrow therapeutic margin and poorly predictable pharmacokinetics, make it a suboptimal drug according to contemporary criteria. Vancomycin is over utilized due to both, overestimation of bacterial infections and, in genuine cases, overestimation of the etiological role of these resistant cocci, either nosocomially or community acquired. New threats narrow further its therapeutic role: poorer outcomes in infections with higher vancomycin MIC and resistance by enterococci. It is frequently given at inappropriate dosage and intervals, failing to: give loading dose when recommended, measure blood levels, adjust dosing to changing renal function and continued use when not necessary. Newer anti staphylococcal drugs haven't replaced completely the role of vancomycin, which maintains its usefulness in contemporary medicine. CONCLUSION: Understanding the strengths and weaknesses of vancomycin, current epidemiology and microbiology of infections for which it may be indicated, as well as the proper administration and monitoring, together with a prudent and selective indication will allow to preserve its present and future utility in the changing medical scenario.


Asunto(s)
Infecciones Estafilocócicas , Vancomicina , Antibacterianos/uso terapéutico , Enterococcus , Humanos , Pruebas de Sensibilidad Microbiana , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus
12.
Rev. chil. infectol ; 34(6): 570-575, dic. 2017. tab, graf
Artículo en Español | LILACS | ID: biblio-899761

RESUMEN

Resumen Introducción: La vigilancia de incidencia de bacterias multi-resistentes es un indicador que permite estimar mejor la magnitud de la resistencia bacteriana en los servicios hospitalarios. Objetivo: Evaluar la incidencia de bacterias multi-resistentes relevantes en unidades de cuidados intensivos del país y establecer las diferencias entre población adulta y pediátrica. Metodología: Se solicitó a los hospitales participantes información del número de aislados de siete bacterias multi-resistentes epidemiológicamente relevantes de unidades de cuidados intensivos (UCI) de adulto y pediátrico entre enero de 2014 y octubre de 2015, y el número de días-cama ocupados en dichas unidades en el mismo período. Con estos datos se calculó incidencia por 1.000 pacientes-día para cada unidad. Resultados: Se recibió información de 20 UCI adultos y 9 UCI pediátricas. En UCI adultos las bacterias de mayor incidencia fueron K. pneumoniae productora de BLEE [4,72 × 1.000 días cama (1,21-13,89)] y S. aureus resistente a oxacilina [3,85 (0,71-12,66)]. En pediatría la incidencia fue menor, destacando K. pneumoniae productora de BLEE [2,71 (0-7,11)] y P. aeruginosa resistente a carbapenémicos [1,61 (0,31-9,25)]. Conclusión: Se observan importantes diferencias entre los distintos hospitales en la incidencia de las bacterias estudiadas. La incidencia de bacterias multi-resistentes en UCI de adultos es significativamente mayor que en UCI pediátrica para la mayoría de las bacterias estudiadas.


Introduction: Incidence of multi-resistant bacteria is an indicator that permits better estimation of the magnitude of bacterial resistance in hospitals. Aim: To evaluate the incidence of relevant multi-drug resistant bacteria in intensive care units (ICUs) of Chile. Methods: Participating hospitals submitted information about the number of isolates from infected or colonized patients with 7 epidemiologically relevant multi-resistant bacteria in adult and pediatric ICUs between January 1, 2014 and October 31, 2015 and the number of bed days occupied in these units in the same period was requested. With these data incidence was calculated per 1,000 patient days for each unit. Results: Information from 20 adults and 9 pediatric ICUs was reviewed. In adult ICUs the bacteria with the highest incidence were K. pneumoniae ESBL [4.72 × 1,000 patient day (1.21-13.89)] and oxacillin -resistant S. aureus [3.85 (0.71-12.66)]. In the pediatric units the incidence was lower, highlighting K. pneumoniae ESBL [2.71 (0-7.11)] and carbapenem -resistant P. aeruginosa [1.61 (0.31-9.25)]. Conclusion: Important differences between hospitals in the incidence of these bacteria were observed. Incidence of multi-resistant bacteria in adult ICU was significantly higher than in pediatric ICU for most of the studied bacterias.


Asunto(s)
Humanos , Niño , Adulto , Bacterias/aislamiento & purificación , Bacterias/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Antibacterianos/farmacología , Valores de Referencia , beta-Lactamasas/aislamiento & purificación , beta-Lactamasas/efectos de los fármacos , Chile , Infección Hospitalaria/microbiología , Incidencia
13.
Rev Chilena Infectol ; 34(3): 243-247, 2017 Jun.
Artículo en Español | MEDLINE | ID: mdl-28991320

RESUMEN

INTRODUCTION: Brucellosis is a zoonosis caused by Brucella spp. It may be acquired by consuming unpasteurized dairy products. Brucellosis has a low incidence in Chile, thus, we have a scarce data. AIM: To report and to characterize the first series of clinical cases of adult patients diagnosed with brucellosis in Chile. METHODS: We describe a series of 13 clinical cases in patients diagnosed between 2000 and 2016 in three different centers in the Metropolitan Region, Chile. A retrospective analysis was performed on clinical presentation, laboratory, antibiotic treatment, morbidity and mortality. RESULTS: The mean age was 50 years old. Eight cases had a record of consumption of unpasteurized dairy products. The most frequently reported complaints were fever. The most frequent focal point involved was the spine. Only one patient had a positive blood culture, while the diagnosis was made using serological techniques in the other part of the group. The most indicated antibiotic regimens were doxycycline-rifampicin and doxycycline-gentamicin. The hospital stay was 20 days approximately as an average. Clinical cure was achieved in all cases. CONCLUSIONS: Brucellosis is an infrequent zoonosis in Chile, and it produces a nonspecific clinical picture, so it is necessary to have high suspicion to make the diagnosis based in the antecedent of consumption of unpasteurized dairy or raw meat.


Asunto(s)
Brucelosis/diagnóstico , Adulto , Anciano , Brucelosis/tratamiento farmacológico , Brucelosis/epidemiología , Brucelosis/etiología , Chile/epidemiología , Productos Lácteos/microbiología , Doxiciclina/administración & dosificación , Quimioterapia Combinada , Femenino , Gentamicinas/administración & dosificación , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Rifampin/administración & dosificación , Población Urbana , Adulto Joven
14.
Rev Chilena Infectol ; 34(2): 156-174, 2017 Apr.
Artículo en Español | MEDLINE | ID: mdl-28632831

RESUMEN

Proper use of antiseptics and disinfectants, is an essential tool to prevent the spread of infectious agents and to control of healthcare-associated infections (HAI). Given the increasing importance of environmental aspects, as well as several advances and updates in the field of its proper use at local and intemational level, the SOCHINF HAI Advisory Committee considers that it is necessary to develop a guide for the rational use of antiseptics and disinfectants, which it will provide consistent scientific basis with that purpose.


Asunto(s)
Comités Consultivos , Antiinfecciosos Locales/administración & dosificación , Infección Hospitalaria/prevención & control , Desinfectantes/administración & dosificación , Sociedades Médicas , Chile , Higiene de las Manos , Directrices para la Planificación en Salud , Humanos
15.
Rev. chil. infectol ; 34(3): 243-247, jun. 2017. tab
Artículo en Español | LILACS | ID: biblio-899707

RESUMEN

Introduction: Brucellosis is a zoonosis caused by Brucella spp. It may be acquired by consuming unpasteurized dairy products. Brucellosis has a low incidence in Chile, thus, we have a scarce data. Aim: To report and to characterize the first series of clinical cases of adult patients diagnosed with brucellosis in Chile. Methods: We describe a series of 13 clinical cases in patients diagnosed between 2000 and 2016 in three different centers in the Metropolitan Region, Chile. A retrospective analysis was performed on clinical presentation, laboratory, antibiotic treatment, morbidity and mortality. Results: The mean age was 50 years old. Eight cases had a record of consumption of unpasteurized dairy products. The most frequently reported complaints were fever. The most frequent focal point involved was the spine. Only one patient had a positive blood culture, while the diagnosis was made using serological techniques in the other part of the group. The most indicated antibiotic regimens were doxycycline-rifampicin and doxycycline-gentamicin. The hospital stay was 20 days approximately as an average. Clinical cure was achieved in all cases. Conclusions: Brucellosis is an infrequent zoonosis in Chile, and it produces a nonspecific clinical picture, so it is necessary to have high suspicion to make the diagnosis based in the antecedent of consumption of unpasteurized dairy or raw meat.


Introducción: La brucelosis es una zoonosis provocada por Brucella spp, cuyo principal mecanismo de transmisión es mediante el consumo de lácteos no pasteurizados. Es de baja ocurrencia en Chile, por lo que los datos locales son escasos. Objetivo: Reportar y caracterizar la primera serie de casos clínicos de pacientes adultos con diagnóstico de brucelosis en Chile. Material y Método: Se describe una serie de 13 casos clínicos en pacientes diagnosticados entre el año 2000 y el 2016 en tres centros de la Región Metropolitana, Chile. Se realizó un análisis retrospectivo acerca de la presentación clínica, laboratorio, tratamiento antimicrobiano y morbi-mortalidad. Resultados: El promedio de edad fue 50 años. Ocho casos tenían antecedente de consumo de lácteos no pasteurizados. El motivo de consulta más frecuente fue sensación febril. El compromiso focal más frecuente fue el de columna vertebral. Sólo en un paciente se encontró hemocultivo positivo; en el resto el diagnóstico se hizo mediante técnicas serológicas. Los esquemas antimicrobianos más indicados fueron doxiciclina-rifampicina y doxiciclina-gentamicina. La estadía hospitalaria fue en promedio de 20 días. En todos los casos se logró curación clínica. Conclusiones: La brucelosis es una zoonosis infrecuente en Chile, produce un cuadro clínico inespecífico, por lo que se debe tener una alta sospecha para realizar el diagnóstico, basada en el antecedente del consumo de productos lácteos no pasteurizados o de carne mal cocida.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Brucelosis/diagnóstico , Rifampin/administración & dosificación , Población Urbana , Brucelosis/etiología , Brucelosis/tratamiento farmacológico , Brucelosis/epidemiología , Gentamicinas/administración & dosificación , Chile/epidemiología , Estudios Retrospectivos , Doxiciclina/administración & dosificación , Productos Lácteos/microbiología , Quimioterapia Combinada , Tiempo de Internación
16.
Rev. chil. infectol ; 34(2): 156-174, abr. 2017. ilus, tab
Artículo en Español | LILACS | ID: biblio-844460

RESUMEN

Proper use of antiseptics and disinfectants, is an essential tool to prevent the spread of infectious agents and to control of healthcare-associated infections (HAI). Given the increasing importance of environmental aspects, as well as several advances and updates in the field of its proper use at local and intemational level, the SOCHINF HAI Advisory Committee considers that it is necessary to develop a guide for the rational use of antiseptics and disinfectants, which it will provide consistent scientific basis with that purpose.


El adecuado uso de antisépticos y desinfectantes, es una herramienta esencial para evitar la diseminación de agentes infecciosos y el control de infecciones asociadas a la atención de salud (IAAS). Dada la importancia creciente de aspectos ambientales, diversos avances y actualizaciones en el ámbito de su correcta utilización en el ámbito local e internacional, el Comité Consultivo de IAAS de Sociedad Chilena de Infectología considera necesario la estructuración de una guía de utilización racional de antisépticos y desinfectantes, que proporcione bases científicas coherentes con dicho propósito.


Asunto(s)
Humanos , Sociedades Médicas , Infección Hospitalaria/prevención & control , Comités Consultivos , Desinfectantes/administración & dosificación , Antiinfecciosos Locales/administración & dosificación , Chile , Higiene de las Manos , Directrices para la Planificación en Salud
17.
Rev Chilena Infectol ; 34(6): 570-575, 2017 Dec.
Artículo en Español | MEDLINE | ID: mdl-29488551

RESUMEN

INTRODUCTION: Incidence of multi-resistant bacteria is an indicator that permits better estimation of the magnitude of bacterial resistance in hospitals. AIM: To evaluate the incidence of relevant multi-drug resistant bacteria in intensive care units (ICUs) of Chile. METHODS: Participating hospitals submitted information about the number of isolates from infected or colonized patients with 7 epidemiologically relevant multi-resistant bacteria in adult and pediatric ICUs between January 1, 2014 and October 31, 2015 and the number of bed days occupied in these units in the same period was requested. With these data incidence was calculated per 1,000 patient days for each unit. RESULTS: Information from 20 adults and 9 pediatric ICUs was reviewed. In adult ICUs the bacteria with the highest incidence were K. pneumoniae ESBL [4.72 × 1,000 patient day (1.21-13.89)] and oxacillin -resistant S. aureus [3.85 (0.71-12.66)]. In the pediatric units the incidence was lower, highlighting K. pneumoniae ESBL [2.71 (0-7.11)] and carbapenem -resistant P. aeruginosa [1.61 (0.31-9.25)]. CONCLUSION: Important differences between hospitals in the incidence of these bacteria were observed. Incidence of multi-resistant bacteria in adult ICU was significantly higher than in pediatric ICU for most of the studied bacterias.


Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Bacterias/aislamiento & purificación , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Adulto , Niño , Chile , Infección Hospitalaria/microbiología , Humanos , Incidencia , Valores de Referencia , beta-Lactamasas/efectos de los fármacos , beta-Lactamasas/aislamiento & purificación
19.
Rev Chilena Infectol ; 32(3): 305-18, 2015 Jun.
Artículo en Español | MEDLINE | ID: mdl-26230437

RESUMEN

Five issues were reviewed in depth at the 2014 annual meeting of Colaborative Group Against Bacterial Resistance and the antecedents and conclusions are detailed in this document. I.- News in CLSI 2014: the difficulties and implications on its implementation at the local level were reviewed and recommendations were set. II.- Criteria for determining the incidence of multi-resistant microorganism in critical care units where indicators and monitoring methodology for better quantification of microorganisms were defined. III.- Quality requirements were established to be considered by the professionals involved in the selection of antimicrobials in the hospital. IV.- Transfer policies, screening and contact precautions for the control of transmission of multiresistant bacteria. V.- Recommendations for health facilities when a carbapenemase producing enterobacteriacea is detected, in a checklist format for rapid deployment in hospitals without endemia of these agents. These are suggestions that arise from the joint work of specialists from many hospitals that do not represent consensus or recommendation, but may help to control the resistance level of each health facility in the country.


Asunto(s)
Antibacterianos/farmacología , Infecciones Bacterianas/microbiología , Farmacorresistencia Bacteriana , Control de Infecciones , Chile , Conducta Cooperativa , Humanos , Pruebas de Sensibilidad Microbiana
20.
Rev. chil. infectol ; 32(3): 305-318, jun. 2015. tab
Artículo en Español | LILACS | ID: lil-753488

RESUMEN

Five issues were reviewed in depth at the 2014 annual meeting of Colaborative Group Against Bacterial Resistance and the antecedents and conclusions are detailed in this document. I.- News in CLSI 2014: the difficulties and implications on its implementation at the local level were reviewed and recommendations were set. II.- Criteria for determining the incidence of multi-resistant microorganism in critical care units where indicators and monitoring methodology for better quantification of microorganisms were defined. III.- Quality requirements were established to be considered by the professionals involved in the selection of antimicrobials in the hospital. IV.- Transfer policies, screening and contact precautions for the control of transmission of multiresistant bacteria. V.- Recommendations for health facilities when a carbapenemase producing enterobacteriacea is detected, in a checklist format for rapid deployment in hospitals without endemia of these agents. These are suggestions that arise from the joint work of specialists from many hospitals that do not represent consensus or recommendation, but may help to control the resistance level of each health facility in the country.


En la reunión anual del Grupo Colaborativo de Resistencia Bacteriana del año 2014 se revisaron en profundidad cinco tópicos cuyos antecedentes y conclusiones se detallan en este documento. Los temas fueron: I.- Novedades del CLSI 2014: se revisaron las dificultades e implicancias de su implementación a nivel local y se establecen recomendaciones. II.- Criterios para la determinación de incidencia de microoganismos multi-resistentes en unidades de pacientes críticos, donde se definieron los indicadores y la metodología de vigilancia para una mejor cuantificación del problema. III.- Se establecieron requisitos de calidad a considerar por los profesionales que participan en la selección de antimicrobianos en el hospital. IV.- Se discutieron las políticas de traslado, tamizaje y precauciones de contacto para el control de la transmisión de bacterias multiresistentes. V.- Se establecieron recomendaciones para los establecimientos de salud frente a la pesquisa de una enterobacteria productora de carbapenemasa en formato de lista de chequeo para la implementación rápida en hospitales sin endemia de estos agentes. Estas sugerencias nacen del trabajo conjunto de especialistas de muchos hospitales, no representan un consenso o normativa pero pueden ser de ayuda para el control de la resistencia en cada establecimiento de salud del país.


Asunto(s)
Humanos , Antibacterianos/farmacología , Infecciones Bacterianas/microbiología , Farmacorresistencia Bacteriana , Control de Infecciones , Chile , Conducta Cooperativa , Pruebas de Sensibilidad Microbiana
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...